Cassava Sciences Inc.

278 articles about Cassava Sciences Inc.

• Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease

  11/4/2020

  Alzheimer’s Patients Treated with Sumifilam Show ed a Statistically Significant (p < 0. 001 ) Treatment Benefit on HMGB1,  a Protein t hat Triggers Neuroinflammation and Loss of Neurons Alzheimer’s Patients Treated with Sumifilam Also Showed a Treatment Benefit (p<0.05) on Blood-brain B arrier Integrity Clinical Data set to be Presented November 7 th at CTAD 2020 C onference

• Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020

  9/30/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13 th international conference on Clinical Trials on Alzheimer’s Disease (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year as

• Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s Disease

  9/14/2020

  Alzheimer’s Patients in Drug Groups Showed Statistically Significant Improvements in Biomarkers of Disease Compared to Placebo Group (P<0.05) Alzheimer’s Patients in Drug Groups Showed Improved Cognition Compared to Placebo Group (Effect Size 46-17%) Sumifilam Was Safe and Well-Tolerated COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 AM ET. Conference Call Will Include Dr. Gonzalez-Rojas, MD, Principal Investigator on Both the Phase 2b Study of Sumifilam and an Ongoing, On

• Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

  9/11/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Monday, September 14th at 8:30 a.m. Eastern Time. 

• Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment Conference

  9/9/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22 nd Annual Global Investment Conference. Event details follow: Date: Tuesday, September 15 th Time: 2:30 p.m. Eastern Time Webcast: https://www.CassavaSciences.com/company-presentations Cassava Sciences’ virtual public

• Cassava Sciences Announces New Patent GrantPatent Protection Runs Through Year 2037, Plus Extensions

  9/3/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it was granted U.S. Patent No. 10,760,052 on September 1, 2020. These patent claims are directed to inhibiting a TLR4-mediated immune response though use of one or more unique filamin A binding molecules. Cassava Sciences’ lead drug candidate, sumifilam, is a novel molecule. The Company’s patent protection in the area

• Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name ‘sumifilam’ by USAN

  8/24/2020

  - Sumifilam Is First of a New Class of Drugs That Target Filamin Proteins - - A Commercial Brand Name for Sumifilam is Expected at a Future Date -

• Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review

  8/12/2020

  - Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease with Lead Drug Candidate, PTI-125, Expected to be Announced September 2020 -  - SavaDx Demonstrates Direct Evidence of Target Engagement & Treatment Effects - - Open-label Study Of PTI-125 Reaches >50% Enrollment - AUSTIN, Texas, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results f

• Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

  7/9/2020

  Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist, Lindsay H. Burns, PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit, a virtual conference, on July 15, 2020.

• Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update

  6/16/2020

  Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes, effective after the close of the U.S. markets on Friday, June 26, 2020. These indexes provide institutional investors and other market participants with exposure to the performance of certain segments of the U.S. stock market. “We are plea

• Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2b Study of PTI-125

  6/3/2020

  - High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results - - Effects Of PTI-125 on Cognition, Other Analysis and Data Expected 2 nd Half 2020 - - Updated Corporate Presentation Now Available on Website -

• Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint

  5/15/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA) today reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in patients with Alzheimer’s disease. This study did not meet its primary endpoint.

• Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

  5/6/2020

  - Anticipates Early Data Readout for Phase 2b Study of PTI-125 in Alzheimer’s Disease - - Approximately $2.9 Million in NIH Research Grants Awarded in 2020 - - Open-Label Study of PTI-125 Initiated in Alzheimer’s Disease -

• Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health

  4/23/2020

  - Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease -

• Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020

  3/26/2020

  Cassava Sciences,, today announced financial results for the year ended December 31, 2019 and provided corporate milestones for 2020.

• Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s DiseaseApproximately 100 Study Participants Will Receive PTI-125 For 12 Months

  3/25/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study to evaluate PTI-125 in patients with Alzheimer’s disease. The Company’s lead investigational drug, PTI-125, seeks to improve both neurodegeneration and neuroinflammation in patients with Alzheimer’s disease. “We believe the ability of our drug to improve multiple function

• Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline

  3/19/2020

  Cassava Sciences, Inc. today announced clinical updates and business progress across its pipeline of product candidates under development.

• Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer’s Disease (JPAD)

  2/11/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients.

• Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019

  12/5/2019

  New Data Shows Clinical Evidence of Target Engagement and Target Validation

• Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

  10/29/2019

  Phase 2a Study Showed Statistically Significant Decreases (p<0.001) in  Clinical Biomarkers of Alzheimer’s Disease